2.60

2.78% 0.08

Compugen Ltd (CGEN)

Overview News Price History Option Chain Discussions Forecast

Compugen Ltd stock is traded at $2.60, with a volume of 448.87K. It is up +2.78% in the last 24 hours and up +61.87% over the past month.

Previous Close:

$2.52

Open:

$2.53

24h Volume:

448.87K

Relative Volume:

0.70

Market Cap:

$208.62M

Revenue:

Net Income/Loss:

$1.60M

P/E Ratio:

86.67

EPS:

0.03

Net Cash Flow:

$-62.91M

1W Performance:

+11.16%

1M Performance:

+61.87%

6M Performance:

+58.90%

1Y Performance:

+23.33%

1-Day Range:

$2.52

$2.645

1-Week Range:

$2.1801

$2.645

52-Week Range:

$1.35

$3.0301

Compugen Ltd Stock (CGEN) Company Profile

Name

Compugen Ltd

Sector

Healthcare (1187)

Industry

Biotechnology (679)

Phone

Address

Employee

Twitter

@CompugenLtd

Next Earnings Date

2024-11-12

Latest SEC Filings

CGEN's Discussions on Twitter

Compare CGEN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CGEN Compugen Ltd	2.60	208.62M	0	1.60M	-62.91M	0.03
VRTX Vertex Pharmaceuticals Inc	474.04	123.91B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	716.08	78.94B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	652.89	39.98B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	274.69	35.89B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	118.71	28.75B	3.30B	-501.07M	1.03B	-2.1146

Compugen Ltd Stock (CGEN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-25	Initiated	Oppenheimer	Outperform
Aug-05-22	Downgrade	Jefferies	Buy → Hold
May-26-20	Resumed	JMP Securities	Mkt Outperform
May-13-20	Initiated	Stifel	Buy
May-07-20	Initiated	SVB Leerink	Outperform
Apr-22-20	Initiated	ROTH Capital	Buy
Mar-24-20	Initiated	SunTrust	Buy
Jan-16-20	Initiated	Cantor Fitzgerald	Overweight
Mar-29-18	Initiated	Oppenheimer	Outperform
Feb-01-16	Resumed	Oppenheimer	Outperform
Oct-15-15	Initiated	FBR Capital	Outperform
Apr-23-15	Resumed	Jefferies	Buy
Apr-21-15	Initiated	Oppenheimer	Outperform
Feb-07-14	Initiated	MLV & Co	Buy
Dec-28-09	Reiterated	Cantor Fitzgerald	Buy
Jul-29-09	Initiated	Cantor Fitzgerald	Buy

View All

Compugen Ltd Stock (CGEN) Latest News

Feb 06, 2025

Views of Wall Street’s Leading Experts on Compugen Ltd - SETE News

Feb 06, 2025

The Psychology of Compugen Ltd Inc. (CGEN) Price Performance: Understanding Market Sentiment - The InvestChronicle

Feb 06, 2025

Insider’s View: Deciphering Compugen Ltd (CGEN)’s Financial Health Through Ratios - The Dwinnex

Feb 06, 2025

Feb 04, 2025

Investing in Compugen Ltd (CGEN) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News

Feb 04, 2025

Major Cancer Immunotherapy Breakthrough Could Be Unveiled at Oppenheimer Conference - StockTitan

Feb 04, 2025

Feb 03, 2025

JPMorgan Chase & Co. Has $122,000 Holdings in Compugen Ltd. (NASDAQ:CGEN) - Defense World

Feb 03, 2025

Feb 01, 2025

Compugen (NASDAQ:CGEN) Stock Passes Above 200-Day Moving AverageHere's Why - MarketBeat

Feb 01, 2025

Jan 30, 2025

CGENCompugen Ltd Latest Stock News & Market Updates - StockTitan

Jan 30, 2025

Jan 21, 2025

Compugen (NASDAQ:CGEN) Share Price Crosses Above Two Hundred Day Moving Average – Should You Sell? - Defense World

Jan 21, 2025

Compugen (NASDAQ:CGEN) Share Price Crosses Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat

Jan 21, 2025

Jan 14, 2025

Has Compugen Ltd.'s (NASDAQ:CGEN) Impressive Stock Performance Got Anything to Do With Its Fundamentals? - Simply Wall St

Jan 14, 2025

Compugen (NASDAQ:CGEN) Now Covered by Oppenheimer - Defense World

Jan 14, 2025

Jan 13, 2025

Compugen Ltd (NASDAQ: CGEN) Gains 3.14% In Early Trade; What Lies Ahead? - Stocks Register

Jan 13, 2025

Oppenheimer Initiates Coverage on Compugen (NASDAQ:CGEN) - MarketBeat

Jan 13, 2025

Oppenheimer starts Compugen at Outperform on immunotherapy candidates' potential By Investing.com - Investing.com Australia

Jan 13, 2025

Oppenheimer starts Compugen at Outperform on immunotherapy candidates' potential - Investing.com India

Jan 13, 2025

Jan 08, 2025

Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid Tumors - Marketscreener.com

Jan 08, 2025

Compugen Launches First-in-Class Cancer Trial with Novel IL-18 Antibody COM503 - StockTitan

Jan 08, 2025

Jan 01, 2025

Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer Therapy - AOL

Jan 01, 2025

Dec 26, 2024

The past five years for Compugen (NASDAQ:CGEN) investors has not been profitable - Yahoo Finance

Dec 26, 2024

Dec 11, 2024

Connor Clark & Lunn Investment Management Ltd. Grows Position in Compugen Ltd. (NASDAQ:CGEN) - Defense World

Nov 30, 2024

Nov 27, 2024

Compugen Bolsters Cancer Therapy Portfolio with New Patent - TipRanks

Nov 27, 2024

Compugen Secures Key Patent for Triple Combination Cancer Immunotherapy Through 2037 | CGEN Stock News - StockTitan

Nov 27, 2024

Nov 24, 2024

Compugen Ltd. (NASDAQ:CGEN) Holdings Raised by Oppenheimer & Co. Inc. - Defense World

Nov 24, 2024

Nov 22, 2024

Compugen (CGEN) Stock Dips Amidst Biotech Sector Movements - GuruFocus.com

Nov 22, 2024

Nov 16, 2024

Compugen Ltd. (NASDAQ:CGEN) Short Interest Down 18.1% in October - MarketBeat

Nov 16, 2024

Nov 15, 2024

Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

Compugen (CGEN) Stock Declines Amidst Industry Downtrend - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Compugen Ltd. (NASDAQ:CGEN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 13, 2024